MYRIAD GENETICS INC

For the period ended Mar 31, 2025. Filed May 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 7, 2025

MYGN$5.67-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 6. Exhibits

10.1	Amendment to Building D Lease Agreement, dated April 10, 2024, between Myriad Genetics, Inc. and ATP SLC D, LLC (incorporated by reference to Exhibit 10.4.2 to the Company’s Annual Report on Form 10-K, File No. 000-26642, filed with the SEC on February 28, 2025).
10.2	Lease Agreement, dated December 1, 2012, by and between Assurex Health, Inc. and the City of Mason, Ohio (incorporated by reference to Exhibit 10.6.1 to the Company’s Annual Report on Form 10-K, File No. 000-26642, filed with the SEC on February 28, 2025).
10.3	Fifth Addendum to Lease Agreement, dated February 20, 2025, between Assurex Health, Inc. and the City of Mason, Ohio (incorporated by reference to Exhibit 10.6.2 to the Company’s Annual Report on Form 10-K, File No. 0-26642, filed with the SEC on February 28, 2025).
10.4+	Amended and Restated Employment Agreement, dated February 24, 2025, between Myriad Genetics, Inc. and Samraat S. Raha (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, File No. 000-26642, filed with the SEC on February 24, 2025).
10.5+	Chief Executive Officer Severance and Change of Control Agreement, dated February 24, 2025, by and between Myriad Genetics, Inc. and Samraat S. Raha (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, File No. 000-26642, filed with the SEC on February 24, 2025).
10.6+	Employment Agreement, dated February 24, 2025, by and between the Company and Mark S. Verratti (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K, File No. 000-26642, filed with the SEC on February 24, 2025).
10.7+	Severance and Change of Control Agreement, dated February 24, 2025, by and between the Company and Mark S. Verratti (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K, File No. 000-26642, filed with the SEC on February 24, 2025).
10.8	Consulting Agreement, dated February 24, 2025, by and between the Company and Paul J. Diaz (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K, File No. 000-26642, filed with the SEC on February 24, 2025).
10.9+	Restricted Stock Unit Agreement, dated May 1, 2025, by and between the Company and Brian Donnelly.
10.10+	Performance-Based Restricted Stock Unit Agreement, dated May 1, 2025, by and between the Company and Brian Donnelly.
31.1	Certification of Chief Executive Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.
32.1	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Furnished).
101.INS	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document.
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104	The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 has been formatted in Inline XBRL.

Management contract or compensatory plan or arrangement.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.